Allogene Therapeutics ALLO 深 滬
已收盤 08-29 16:00:00 美东时间
1.13
-0.050
-4.24%
華盛通- 最 高1.20
- 今 開1.18
- 成交量 334.43万股
- 最 低 1.11
- 昨 收 1.18
- 總市值 2.47亿
- 52周最高 3.78
- 市盈率 靜 --
- 換手率 1.53%
- 52周最低 0.8621
- 委 比 70.09%
- 總股本 2.19亿
- 歷史最高 55.00
- 量 比 0.71
- 振 幅 7.63%
- 歷史最低 0.8621
- 每 手 1
- 風險率 0.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Allogene Therapeutics Announces Participation in Upcoming Investor Conference
Allogene Therapeutics will participate in Citi's 2025 Biopharma Back to School Summit on September 3 at 7:30AM PT/10:30AM ET. Live webcasts and a replay will be available on the company's website under the Investors section. Allogene focuses on developing allogeneic CAR T products for cancer and autoimmune diseases to deliver scalable, ready-to-use cell therapies.
08-27 12:30
Marker Therapeutics Stock Drops After Report About Lymphoma Treatment
Marker Therapeutics reports strong safety and efficacy data for MT-601 in lymphoma patients, with durable responses and no serious adverse events.
08-27 00:34
Allogene Therapeutics Advances in CAR T Cell Therapy
Allogene Therapeutics ( ($ALLO) ) has released its Q2 earnings. Here is a break...
08-14 11:57
Allogene Therapeutics Q2 EPS $(0.23) Beats $(0.28) Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.28) by 18.15 percent. This is a 34.29 percent increase over losses of $(0.35) per share
08-14 04:38
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
A Look at Allogene Therapeutics's Upcoming Earnings Report
Allogene Therapeutics (NASDAQ:ALLO) is preparing to release its quarterly earni...
08-13 02:02
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
Allogene Therapeutics will report its Q2 2025 financial results and provide a business update on August 13, 2025, followed by a live webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. The listen-only webcast will be available at www.allogene.com under the Investors tab, with a replay accessible for 30 days. To ask questions during the call, registration is required via a provided link to receive a personal PIN. Allogene, headquartered in S...
08-06 12:30
JMP Securities Reiterates Market Perform on Allogene Therapeuticsto Market Perform
JMP Securities analyst Reni Benjamin reiterates Allogene Therapeutics (NASDAQ:ALLO) from Market Perform to Market Perform.
08-04 22:28
JP Morgan Downgrades Allogene Therapeutics to Neutral
JP Morgan analyst Brian Cheng downgrades Allogene Therapeutics (NASDAQ:ALLO) from Overweight to Neutral.
08-04 18:00
Allogene Therapeutics Selects Selected Standard Fludarabine And Cyclophosphamide As Lymphodepletion Regimen To Be Used In ALPHA3 Study Evaluating Cemacabtagene Ansegedleucel In First-line Consolidation For Large B-Cell Lymphoma
Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee, and in Consultation with the FDA Following an ALLO-647-Related Death in the FCA
08-01 20:37
